{"title":"血浆消毒器与传统层流室在异基因造血干细胞移植受者中的比较。","authors":"Ting Wang, Yi Xia, Wei Hu, Boning Liu, Xiaohui Zhang, Wenxuan Huo, Jun Kong, Yaru Ma, Wenwen Xiao, Ce Shi, Qixin Du, Leqing Cao, Dong Han, Dongyue Yao, Hongyue Yin, Daoxing Deng, Jingyu Gao, Yashu Jia, Jiating Wang, Jing Liu, Xiaoshuang Han, Junxia Wang, Ling Ma, Yunjing Xia, Shanshan Hu, Yuanyuan Zhang, Fengmei Zheng, Xiaojun Huang, Xiaodong Mo","doi":"10.1177/09636897251335722","DOIUrl":null,"url":null,"abstract":"<p><p>Patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) are typically placed in a laminar air flow room until hematopoietic reconstitution occurs. In this study, we compared the differences in clinical outcomes between patients receiving allo-HSCT in a conventional laminar flow room (<i>n</i> = 200) and those receiving allo-HSCT in a plasma sterilizer environment (<i>n</i> = 201). The overall infection rates (20.4% vs 25.5%, <i>P</i> = 0.224) and the sites of infection (sepsis, perianal infection, and catheter-related infection) were comparable between the two groups. Additionally, the engraftment times were comparable between the two groups in terms of time to allo-HSCT, leukocyte engraftment time, and platelet engraftment time. The 100-day posttransplantation clinical outcomes were also comparable between the two groups in terms of the probability of overall survival (98.5% vs 99.5%, <i>P</i> = 0.316), leukemia-free survival (96.5% vs 96.5%, <i>P</i> = 0.991), the cumulative incidence of relapse (2.0% vs 3.0%, <i>P</i> = 0.523), non-relapse mortality (1.5% vs 0.5%, <i>P</i> = 0.316) and acute graft-versus-host disease (23.4% vs 22.0%, <i>P</i> = 0.723). Thus, our results demonstrated that receiving allo-HSCT via a plasma sterilizer did not increase the risk of pre-engraftment infection, and the clinical outcomes of these patients were comparable to those of patients in a conventional laminar flow room.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"34 ","pages":"9636897251335722"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046171/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipients.\",\"authors\":\"Ting Wang, Yi Xia, Wei Hu, Boning Liu, Xiaohui Zhang, Wenxuan Huo, Jun Kong, Yaru Ma, Wenwen Xiao, Ce Shi, Qixin Du, Leqing Cao, Dong Han, Dongyue Yao, Hongyue Yin, Daoxing Deng, Jingyu Gao, Yashu Jia, Jiating Wang, Jing Liu, Xiaoshuang Han, Junxia Wang, Ling Ma, Yunjing Xia, Shanshan Hu, Yuanyuan Zhang, Fengmei Zheng, Xiaojun Huang, Xiaodong Mo\",\"doi\":\"10.1177/09636897251335722\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) are typically placed in a laminar air flow room until hematopoietic reconstitution occurs. In this study, we compared the differences in clinical outcomes between patients receiving allo-HSCT in a conventional laminar flow room (<i>n</i> = 200) and those receiving allo-HSCT in a plasma sterilizer environment (<i>n</i> = 201). The overall infection rates (20.4% vs 25.5%, <i>P</i> = 0.224) and the sites of infection (sepsis, perianal infection, and catheter-related infection) were comparable between the two groups. Additionally, the engraftment times were comparable between the two groups in terms of time to allo-HSCT, leukocyte engraftment time, and platelet engraftment time. The 100-day posttransplantation clinical outcomes were also comparable between the two groups in terms of the probability of overall survival (98.5% vs 99.5%, <i>P</i> = 0.316), leukemia-free survival (96.5% vs 96.5%, <i>P</i> = 0.991), the cumulative incidence of relapse (2.0% vs 3.0%, <i>P</i> = 0.523), non-relapse mortality (1.5% vs 0.5%, <i>P</i> = 0.316) and acute graft-versus-host disease (23.4% vs 22.0%, <i>P</i> = 0.723). Thus, our results demonstrated that receiving allo-HSCT via a plasma sterilizer did not increase the risk of pre-engraftment infection, and the clinical outcomes of these patients were comparable to those of patients in a conventional laminar flow room.</p>\",\"PeriodicalId\":9721,\"journal\":{\"name\":\"Cell Transplantation\",\"volume\":\"34 \",\"pages\":\"9636897251335722\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12046171/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cell Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/09636897251335722\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CELL & TISSUE ENGINEERING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/09636897251335722","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}
引用次数: 0
摘要
接受同种异体造血干细胞移植(allo-HSCT)的患者通常被放置在层流空气室,直到造血重建发生。在这项研究中,我们比较了在传统层流室接受同种异体造血干细胞移植的患者(n = 200)和在血浆灭菌器环境中接受同种异体造血干细胞移植的患者(n = 201)的临床结果差异。两组总感染率(20.4% vs 25.5%, P = 0.224)和感染部位(脓毒症、肛周感染和导管相关感染)具有可比性。此外,两组移植时间在同种异体造血干细胞移植时间、白细胞移植时间和血小板移植时间方面具有可比性。两组移植后100天的临床结果在总生存率(98.5% vs 99.5%, P = 0.316)、无白血病生存率(96.5% vs 96.5%, P = 0.991)、累计复发率(2.0% vs 3.0%, P = 0.523)、非复发死亡率(1.5% vs 0.5%, P = 0.316)和急性移植物抗宿主病(23.4% vs 22.0%, P = 0.723)方面也具有可比性。因此,我们的研究结果表明,通过血浆消毒器接受同种异体造血干细胞移植不会增加植入前感染的风险,这些患者的临床结果与在传统层流室接受同种异体造血干细胞移植的患者相当。
Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipients.
Patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) are typically placed in a laminar air flow room until hematopoietic reconstitution occurs. In this study, we compared the differences in clinical outcomes between patients receiving allo-HSCT in a conventional laminar flow room (n = 200) and those receiving allo-HSCT in a plasma sterilizer environment (n = 201). The overall infection rates (20.4% vs 25.5%, P = 0.224) and the sites of infection (sepsis, perianal infection, and catheter-related infection) were comparable between the two groups. Additionally, the engraftment times were comparable between the two groups in terms of time to allo-HSCT, leukocyte engraftment time, and platelet engraftment time. The 100-day posttransplantation clinical outcomes were also comparable between the two groups in terms of the probability of overall survival (98.5% vs 99.5%, P = 0.316), leukemia-free survival (96.5% vs 96.5%, P = 0.991), the cumulative incidence of relapse (2.0% vs 3.0%, P = 0.523), non-relapse mortality (1.5% vs 0.5%, P = 0.316) and acute graft-versus-host disease (23.4% vs 22.0%, P = 0.723). Thus, our results demonstrated that receiving allo-HSCT via a plasma sterilizer did not increase the risk of pre-engraftment infection, and the clinical outcomes of these patients were comparable to those of patients in a conventional laminar flow room.
期刊介绍:
Cell Transplantation, The Regenerative Medicine Journal is an open access, peer reviewed journal that is published 12 times annually. Cell Transplantation is a multi-disciplinary forum for publication of articles on cell transplantation and its applications to human diseases. Articles focus on a myriad of topics including the physiological, medical, pre-clinical, tissue engineering, stem cell, and device-oriented aspects of the nervous, endocrine, cardiovascular, and endothelial systems, as well as genetically engineered cells. Cell Transplantation also reports on relevant technological advances, clinical studies, and regulatory considerations related to the implantation of cells into the body in order to provide complete coverage of the field.